Back to Search
MICHAEL EWER, M.D.
M.D.
Cardiovascular Disease Physician
NPI: 1669540142IndividualAccepts Medicare
Specialties, Licenses & Credentials
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
E5064(TX)
Education
OTHER
Class of 1969
Research & Publications (20)
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.
PMID 19474115·Ann Oncol·2009
4-observational
A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health.
PMID 19235248·Cancer·2009
6-review
Sunitinib-related cardiotoxicity: an interdisciplinary issue.
PMID 18490940·Nat Clin Pract Cardiovasc Med·2008
8-other
Is trastuzumab associated with adverse cardiac effects in patients with breast cancer?
PMID 18212766·Nat Clin Pract Oncol·2008
8-other
Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.
PMID 17592672·Clin Breast Cancer·2007
6-review
Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
PMID 16258084·J Clin Oncol·2005
4-observational
Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.
PMID 15860848·J Clin Oncol·2005
8-other
Characteristics of cardiac arrest in cancer patients as a predictor of survival after cardiopulmonary resuscitation.
PMID 11745264·Cancer·2001
8-other
Anthracycline cardiotoxicity: why are we still interested?
PMID 19418824·Oncology (Williston Park)·2009
8-other
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.
PMID 18533085·Mayo Clin Proc·2008
8-other
Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?
PMID 18227525·J Clin Oncol·2008
8-other
Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.
PMID 18203425·Int J Nanomedicine·2007
6-review
Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?
PMID 18048835·J Clin Oncol·2007
8-other
The anthracycline-trastuzumab interaction: Up-regulated binding may provide vital mechanistic insight.
PMID 17719769·Eur J Cancer·2007
8-other
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
PMID 17200359·Clin Cancer Res·2007
3-trial
Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.
PMID 17020459·Expert Rev Anticancer Ther·2006
6-review
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
PMID 16258083·J Clin Oncol·2005
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1669540142
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 57
- Publications
- 20
Are you this provider?
Claim Your Profile